Odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
Patent Information
- Application Number
- JP2023528445
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-14
- Filing Date
- 2021-11-12
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000088_0000 
Figure 00000088_0001 
Figure 00000088_0002
Abstract
Claims
1. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis (PFIC) or pruritus associated with progressive familial intrahepatic cholestasis (PFIC), wherein following oral administration of the pharmaceutical formulation to a subject, the subject exhibits a reduction in average monthly pruritus score.
2. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in reducing the mean monthly pruritus score in subjects with progressive familial intrahepatic cholestasis (PFIC).
3. 3. The pharmaceutical formulation for use according to any one of claims 1 to 2, wherein the reduction in the mean monthly pruritus score is at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.9, at least 1.0, at least 1.1, at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1.8, at least 1.9, or at least 2.
0.
4. 4. The pharmaceutical formulation for use according to any one of claims 1 to 3, wherein the reduction in the average monthly pruritus score is from about 1.2 to about 2.
0.
5. The pharmaceutical formulation for use according to any one of claims 1 to 4, wherein the reduction in the average monthly pruritus score is about 1.
6.
6. 6. The pharmaceutical formulation for use according to any one of claims 1 to 5, wherein said reduction in average monthly pruritus score occurs after at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks of administration of said pharmaceutical formulation.
7. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis (PFIC) or pruritus associated with progressive familial intrahepatic cholestasis (PFIC), wherein following oral administration of the pharmaceutical formulation to a subject, the subject exhibits a decrease in mean serum bile acid concentrations.
8. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in lowering mean serum bile acid concentrations in subjects with progressive familial intrahepatic cholestasis (PFIC).
9. 9. The pharmaceutical formulation for use according to any one of claims 7 to 8, wherein the reduction in mean serum bile acid concentration is at least 50 μmol / L, at least 75 μmol / L, at least 100 μmol / L, at least 12.5 μmol / L, at least 150 μmol / L, or at least 175 μmol / L compared to baseline.
10. 9. The pharmaceutical formulation for use according to any one of claims 7 to 8, wherein the reduction in mean serum bile acid concentration is from about 50 μmol / L to about 180 μmol / L compared to baseline.
11. 9. The pharmaceutical formulation for use according to any one of claims 7 to 8, wherein the reduction in mean serum bile acid concentration is from about 70 μmol / L to about 120 μmol / L compared to baseline.
12. 12. The pharmaceutical formulation for use according to any one of claims 7 to 11, wherein the reduction in mean serum bile acid concentration occurs after at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks of administration of the pharmaceutical formulation.
13. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis (PFIC) or pruritus associated with progressive familial intrahepatic cholestasis (PFIC), wherein after oral administration of the pharmaceutical formulation to a subject for at least 24 weeks, the subject exhibits a serum bile acid concentration of less than 70 μmol / L.
14. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis (PFIC) or pruritus associated with progressive familial intrahepatic cholestasis (PFIC), wherein after oral administration of the pharmaceutical formulation to a subject for at least 24 weeks, the subject exhibits at least a 50% decrease in serum bile acid concentrations compared to baseline.
15. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in reducing serum bile acid concentrations by at least 50% compared to baseline in subjects with progressive familial intrahepatic cholestasis (PFIC) by oral administration of said pharmaceutical formulation for at least 24 weeks.
16. 16. The pharmaceutical formulation for use according to any one of claims 14 to 15, wherein the subject exhibits a reduction in serum bile acid concentration of at least 60%, at least 70%, or at least 80% compared to baseline.
17. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis (PFIC) or pruritus associated with progressive familial intrahepatic cholestasis (PFIC), wherein the subject exhibits an increase in mean height Z-score compared to baseline.
18. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in increasing mean height Z-score compared to baseline in a subject with progressive familial intrahepatic cholestasis (PFIC).
19. 19. The pharmaceutical formulation for use according to any one of claims 17 to 18, wherein the increase in mean height Z-score is at least 0.5, at least 0.75, at least 1, at least 1.25, or at least 1.5 compared to baseline.
20. 19. The pharmaceutical formulation for use according to any one of claims 17 to 18, wherein the increase in mean height Z-score occurs after at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks of administration of the pharmaceutical formulation.
21. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis (PFIC) or pruritus associated with progressive familial intrahepatic cholestasis (PFIC), wherein following oral administration of the pharmaceutical formulation to a subject, the subject exhibits an increase in mean body weight Z-score.
22. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in increasing mean body weight Z-score in subjects with progressive familial intrahepatic cholestasis (PFIC).
23. 23. The pharmaceutical formulation for use according to any one of claims 21 to 22, wherein the increase in mean body weight Z-score is at least 0.2, at least 0.4, at least 0.6, at least 0.8, at least 1, at least 1.2, or at least 1.
4.
24. 23. The pharmaceutical formulation for use according to any one of claims 21 to 22, wherein said increase occurs after at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks of administration of said pharmaceutical formulation.
25. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in improving sleep parameters in a subject with PFIC.
26. 26. The pharmaceutical formulation for use according to claim 25, wherein said sleep parameters are selected from the group consisting of: percentage of days with bleeding-related scratching, percentage of days needing assistance falling asleep, percentage of days needing sedation, and percentage of days needing to sleep with a caregiver.
27. 27. The pharmaceutical formulation for use according to claim 25 or 26, wherein the improvement in sleep parameters occurs after at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks, at least 28 weeks, at least 32 weeks, at least 36 weeks, at least 40 weeks, or at least 48 weeks of administration of the pharmaceutical formulation.
28. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in improving liver parameters in a subject with PFIC.
29. 29. The pharmaceutical formulation for use according to claim 28, wherein the liver parameter is selected from the group consisting of autotaxin levels, plasma C4 levels, total bilirubin levels, serum alanine aminotransferase (ALT) levels, and serum aspartate transaminase (AST) levels.
30. 30. The pharmaceutical formulation for use according to claim 28 or 29, wherein the improvement in the liver parameter occurs after administration of the pharmaceutical formulation for at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks, at least 28 weeks, at least 32 weeks, at least 36 weeks, at least 40 weeks, or at least 48 weeks.
31. 1. A pharmaceutical formulation comprising odevixibat or a pharma- ceutical acceptable salt thereof for use in the treatment of progressive familial intrahepatic cholestasis 2 (PFIC2), wherein after oral administration of the pharmaceutical formulation to a subject for at least 48 weeks, the subject exhibits serum bile acid concentrations below the disease-modifying threshold for PFIC2.
32. The pharmaceutical formulation for use according to any one of claims 1 to 30, wherein the PFIC is PFIC1.
33. The pharmaceutical formulation for use according to any one of claims 1 to 30, wherein the PFIC is PFIC2.
34. The pharmaceutical formulation for use according to any one of claims 1 to 30, wherein the PFIC is PFIC3.
35. The pharmaceutical formulation for use according to any one of claims 1 to 30, wherein the PFIC is PFIC6.
36. The pharmaceutical formulation for use according to any one of claims 1 to 35, wherein the subject is a pediatric subject.
37. The pharmaceutical formulation for use according to any one of claims 1 to 36, wherein the subject is administered 120 μg / kg / day of odevixibat or a pharma- ceutically acceptable salt thereof.
38. The pharmaceutical formulation for use according to any one of claims 1 to 37, wherein the subject is administered 40 μg / kg / day of odevixibat or a pharma- ceutically acceptable salt thereof.
39. 39. The pharmaceutical formulation for use according to any one of claims 1 to 38, wherein the subject was naïve to odevixibat prior to the first administration of the pharmaceutical formulation comprising odevixibat or a pharma- ceutically acceptable salt thereof.
40. 40. The pharmaceutical formulation of odevixibat or a pharma- ceutically acceptable salt thereof for use according to any one of claims 1 to 39, wherein the pharmaceutical formulation of odevixibat or a pharma- ceutically acceptable salt thereof comprises a plurality of particles, each particle being from about 0.1 to about 1.5 nm in size, and comprising odevixibat or a pharma- ceutically acceptable salt thereof in an amount of from about 0.1% (w / w) to about 5.0% (w / w) based on the total weight of the particles.
41. 41. The pharmaceutical formulation for use according to claim 40, wherein each particle comprises odevixibat or a pharma- ceutically acceptable salt thereof in an amount of about 0.5% (w / w) to about 2.0% (w / w) based on the total weight of the particle.
42. 42. The pharmaceutical formulation for use according to claim 40 or 41, wherein each particle comprises odevixibat or a pharma- ceutically acceptable salt thereof in an amount of about 0.5% (w / w) based on the total weight of the particle.
43. 43. The pharmaceutical formulation for use according to any one of claims 40 to 42, wherein each particle comprises odevixibat or a pharma- ceutically acceptable salt thereof in an amount of about 1.5% (w / w) based on the total weight of the particle.
44. A pharmaceutical formulation for use according to any one of claims 40 to 43, wherein each particle comprises a core and a coating layer surrounding said core.
45. The pharmaceutical formulation for use according to any one of claims 40 to 44, wherein the core does not contain odevixibat or a pharma- ceutically acceptable salt thereof.
46. 46. The pharmaceutical formulation for use according to any one of claims 40 to 45, wherein the core comprises microcrystalline cellulose.
47. The pharmaceutical formulation for use according to any one of claims 44 to 46, wherein the coating layer comprises odevixibat or a pharma- ceutically acceptable salt thereof.
48. The pharmaceutical formulation for use according to any one of claims 44 to 47, wherein said coating layer comprises a film-forming polymer.
49. The pharmaceutical formulation for use according to any one of claims 44 to 48, wherein the coating layer is sprayed onto the particles as a homogenous aqueous suspension of odevixibat.
50. 50. The pharmaceutical formulation for use according to claim 49, wherein the homogenous suspension is prepared by dispersing odevixibat or a pharma- ceutically acceptable salt thereof in water by wet milling.
51. 51. The pharmaceutical formulation for use according to claim 49 or 50, wherein the homogenous suspension does not contain aggregates of odevixibat greater than 200 μm.
52. The pharmaceutical formulation for use according to any one of claims 44 to 51, wherein said coating layer is free of surfactants.
53. 53. The pharmaceutical formulation for use according to any one of claims 40 to 52, wherein the particles are from about 0.1 to about 1.0 mm in size.
54. The pharmaceutical formulation for use according to any one of claims 40 to 53, wherein odevixibat is present as a crystalline hydrate of odevixibat.
55. 55. The pharmaceutical formulation for use according to any one of claims 40 to 54, wherein odevixibat is present as a crystalline modification 1 of odevixibat having an X-ray powder diffraction (XRPD) pattern obtained by CuKα1 radiation with at least specific peaks at 2θ positions 5.6±0.2, 6.7±0.2, and / or 12.1±0.
2.
56. The pharmaceutical formulation for use according to any one of claims 1 to 39, wherein odevixibat is present as a hydrate of odevixibat.
57. 57. The pharmaceutical formulation for use according to claim 56, wherein odevixibat is present as a sesquihydrate.
58. 58. The pharmaceutical formulation for use according to any one of claims 1 to 39 and 56 to 57, wherein odevixibat is present as a crystalline hydrate of odevixibat.
59. 59. The pharmaceutical formulation for use according to claim 58, wherein odevixibat is present as a crystalline modification 1 of odevixibat having an X-ray powder diffraction (XRPD) pattern obtained by CuKα1 radiation with at least specific peaks at 2θ positions 5.6±0.2, 6.7±0.2, and / or 12.1±0.2.
